Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OSI Looks To CRO To Develop Oncologic Agent Following Pfizer Divestiture

Executive Summary

OSI Pharmaceuticals is planning to turn development of its oncologic CP-358,774 over to a contract research organization following termination of OSI's development collaboration with Pfizer.

You may also be interested in...



Pfizer On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships: An Interview With PharmAsia News (Part 2 of 2)

On the way back to his old job in the U.S., after a stint in Shanghai as head of research in Asia, VP Richard Connell, head of Preclinical Outsourcing says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.

First Horizon Pharmaceuticals’ Cognex (correction)

First Horizon owns Alzheimer's disease agent Cognex; company purchased rights from Warner-Lambert in 2000 ahead of the Pfizer merger (1"The Pink Sheet" June 26, 2000, p. 20). "The Pink Sheet" incorrectly reported the product as a Pfizer drug in the Oct. 20 issue...

First Horizon Pharmaceuticals’ Cognex (correction)

First Horizon owns Alzheimer's disease agent Cognex; company purchased rights from Warner-Lambert in 2000 ahead of the Pfizer merger (1"The Pink Sheet" June 26, 2000, p. 20). "The Pink Sheet" incorrectly reported the product as a Pfizer drug in the Oct. 20 issue...

Related Content

UsernamePublicRestriction

Register

PS036245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel